Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Trial Profile

Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Resiquimod (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Sponsors Spirig Pharma
  • Most Recent Events

    • 24 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01808950).
    • 08 Mar 2013 Planned End Date changed from 15 Oct 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top